6533b7d8fe1ef96bd126986c
RESEARCH PRODUCT
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D GargLorenzo EgalluzziLorenzo EgalluzziLorenzo EgalluzziLorenzo EgalluzziLorenzo EgalluzziLionel ApetohLionel EapetohLionel EapetohThais EbaertThais EbaertRaymond B BirgeJose Manuel Bravo-san PedroJose Manuel Bravo-san PedroJose Manuel Bravo-san PedroJose Manuel Bravo-san PedroJose Manuel Bravo-san PedroKarine EbreckpotDavid EbroughRicardo EchaurioMara EcironeAn EcoosemansAn EcoosemansPierre G CoulieDirk Ede RuysscherLuciana EdiniPeter Ede WitteAleksandra M Dudek-pericAlberto EfaggioniJitka EfucikovaJitka EfucikovaUdo S GaiplJakub EgolabMarie-lise EgougeonMichael R HamblinAkseli EhemminkiAkseli EhemminkiAkseli EhemminkiMartin EherrmannJames W. HodgeOliver EkeppOliver EkeppOliver EkeppOliver EkeppOliver EkeppGuido EkroemerGuido EkroemerGuido EkroemerGuido EkroemerGuido EkroemerGuido EkroemerGuido EkroemerDmitri V KryskoDmitri V KryskoWalter G LandFrank EmadeoFrank EmadeoAngelo A. ManfrediStephen R. MattarolloChristian EmaueroderNicolò EmerendinoGabriele EmulthoffThomas EpabstJean-ehrland EricciChiara ErigantiErminia EromanoNicole ErufoMark J. SmythMark J. SmythJürgen EsonnemannRadek EspisekRadek EspisekJohn EstaggErika VacchelliErika EvacchelliErika EvacchelliErika EvacchelliErika EvacchelliPeter EvandenabeelePeter EvandenabeeleLien EvandenberkBenoit J Van Den EyndeStefaan Willy Van GoolFrancesca EvelottiLaurence EzitvogelLaurence EzitvogelLaurence EzitvogelLaurence EzitvogelPatrizia Eagostinissubject
medicine.medical_treatmentAPOPTOTIC CALRETICULIN EXPOSUREanti-tumor immunityimmunogenicityPHOTODYNAMIC THERAPY0302 clinical medicinetranslational medicineoncoimmunologyImmunology and AllergyCytotoxic T cellMedicineAnti-tumor immunity; Immunogenicity; Immunotherapy; Molecular medicine; Oncoimmunology; Patient prognosis; Translational medicine; Immunology; Immunology and Allergy0303 health sciencesanti-tumor immunity; immunogenicity; immunotherapy; molecular medicine; oncoimmunology; patient prognosis; translational medicineRIBOSOMAL-PROTEIN DIMERClassificationddc:3. Good health030220 oncology & carcinogenesisImmunogenic cell deathMolecular MedicineimmunotherapyACTIVATING POLYPEPTIDE-IIHIGH HYDROSTATIC-PRESSURElcsh:Immunologic diseases. AllergyANTICANCER IMMUNE-RESPONSESImmunology3122 Cancers610 Medicine & healthpatient prognosis03 medical and health sciencesImmune systemHUMAN TUMOR-CELLSFORMYL PEPTIDE RECEPTORS030304 developmental biologybusiness.industryTranslational medicineBiology and Life SciencesCYTOTOXIC T-LYMPHOCYTESImmunotherapyDendritic cellMolecular medicineNEGATIVE BREAST-CANCERImmunologyCancer cellmolecular dicine3111 Biomedicinebusinesslcsh:RC581-607description
The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by cells succumbing to immunogenic cell death (ICD) favors the establishment of a productive interface with the immune system. This results in the elicitation of tumor-targeting immune responses associated with the elimination of residual, treatment-resistant cancer cells, as well as with the establishment of immunological memory. Although ICD has been characterized with increased precision since its discovery, several questions remain to be addressed. Here, we summarize and tabulate the main molecular, immunological, preclinical, and clinical aspects of ICD, in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation. ispartof: Frontiers in Immunology vol:6 issue:NOV ispartof: location:Switzerland status: published
year | journal | country | edition | language |
---|---|---|---|---|
2015-11-20 | Frontiers in Immunology |